| 5th Jul 2022 7:00 am |
RNS |
New XF-73 research programme |
| 8th Jun 2022 7:00 am |
RNS |
Grant of share options |
| 27th May 2022 11:56 am |
RNS |
Result of Annual General Meeting & Strategy Update |
| 26th May 2022 7:00 am |
RNS |
Board Changes |
| 12th May 2022 7:00 am |
RNS |
Landmark NTCD-M3 data to be presented at Anaerobe |
| 3rd May 2022 7:00 am |
RNS |
Destiny Pharma appoints Dr Yuri Martina as CMO |
| 27th Apr 2022 3:34 pm |
RNS |
Posting of Annual Report and Notice of AGM |
| 26th Apr 2022 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 12th Apr 2022 7:00 am |
RNS |
Audited results for year ended 31 December 2021 |
| 4th Apr 2022 2:45 pm |
RNS |
Notice of Results |
| 4th Apr 2022 2:37 pm |
RNS |
Notification of Major Holdings |
| 31st Mar 2022 7:00 am |
RNS |
To present data at ECCMID Congress |
| 28th Mar 2022 11:30 am |
RNS |
Result of General Meeting and Total Voting Rights |
| 25th Mar 2022 7:00 am |
RNS |
Result of Open Offer |
| 22nd Mar 2022 10:30 am |
RNS |
Exercise of Options and Total Voting Rights |
| 8th Mar 2022 12:30 pm |
RNS |
Fundraising |
| 8th Feb 2022 7:00 am |
RNS |
Positive feedback from EMA on XF-73 Nasal gel Ph 3 |
| 1st Feb 2022 4:11 pm |
RNS |
Exercise of Options and Total Voting Rights |
| 1st Feb 2022 7:00 am |
RNS |
Positive data in XF-73 Dermal study with NIAID |
| 31st Jan 2022 2:30 pm |
RNS |
Exercise of Options and Total Voting Rights |
| 25th Jan 2022 7:00 am |
RNS |
Grant of share options |
| 24th Jan 2022 7:00 am |
RNS |
Clinical and commercial opportunity of NTCD-M3 |
| 21st Jan 2022 7:15 am |
RNS |
Destiny Pharma Lancet Report |
| 17th Jan 2022 7:00 am |
RNS |
Strategy/Company/Ops Update |
| 21st Dec 2021 4:35 pm |
RNS |
Exercise of Options and Total Voting Rights |
| 17th Dec 2021 9:46 am |
RNS |
Grant of share options |
| 15th Nov 2021 2:26 pm |
RNS |
Directorate Change |
| 4th Nov 2021 7:00 am |
RNS |
SAB Member Prof. Gerding is Keynote at C.diff Conf |
| 18th Oct 2021 7:00 am |
RNS |
Study gives strong support for potential of XF-73 |
| 27th Sep 2021 3:18 pm |
RNS |
Director/PDMR Shareholding |
| 27th Sep 2021 7:00 am |
RNS |
Expansion of clinical pipeline |
| 9th Sep 2021 7:00 am |
RNS |
Interim results for six months ended 30 June 2021 |
| 23rd Aug 2021 7:00 am |
RNS |
Notice of Interim Results |
| 2nd Aug 2021 7:00 am |
RNS |
Secondary endpoint analysis from Phase 2b trial |
| 9th Jul 2021 8:00 am |
RNS |
XF-73 Phase 2b data to be presented at ECCMID |
| 6th Jul 2021 7:00 am |
RNS |
NTCD-M3 RD Agreement with US Dept Veterans Affairs |
| 2nd Jul 2021 8:00 am |
RNS |
Scientific Advisor Gerding chairs C Diff symposium |
| 29th Jun 2021 8:24 am |
RNS |
DEST to present at Shares & AJ Bell Webinar 6/7/21 |
| 10th Jun 2021 5:00 pm |
RNS |
Director Dealing |
| 10th Jun 2021 7:00 am |
RNS |
XF-73 data abstract to be presented at 2021 ECCMID |
